nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

27.08.2020 | COVID-19 | Brief Report Zur Zeit gratis

RETRACTED ARTICLE: A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

verfasst von: Yasemin Cag, Sacit Icten, Burcu Isik-Goren, Naciye Betul Baysal, Begum Bektas, Ece Selvi, Pinar Ergen, Ozlem Aydin, Ayse Canan Ucisik, Fatma Yilmaz-Karadag, Hulya Caskurlu, Tulin Akarsu-Ayazoglu, Hasan Kocoglu, Sinan Uzman, Muge Nural-Pamukcu, Ferhat Arslan, Gurhan Bas, Mahmut Tayyar Kalcioglu, Haluk Vahaboglu

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

This manuscript aims to present a treatment algorithm we applied to manage COVID-19 patients admitted to our hospital. During the study period, 2043 patients with suspected COVID-19 were admitted to the emergency department. Molecular tests indicated that 475 of these patients tested positive for COVID-19. We administered hydroxychloroquine plus doxycycline to mild cases (isolated at home) for 3 days and lopinavir plus doxycycline to moderate and severe cases (hospitalized) for 5 days. The overall case fatality rate was 4.2% (20/475).

Zhu N, Zhang D, Wang W, Li XX, Yang B, Song J, et al. A Novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med [Internet] 2020 20 [cited 2020 12];382:NEJMoa2001017. https://doi.org/10.1056/NEJMoa2001017

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323. https://doi.org/10.1001/jama.2020.2648

Ioannidis JPA (2020) Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures. Eur J Clin Investig:e13222. https://doi.org/10.1111/eci.13222

Martin S, Karafillakis E, Preet R, Wilder-Smith A The pandemic of social media panic travels faster than the COVID-19 outbreak. Artic J Travel Med [Internet] 2020 [cited 2020 26];https://doi.org/10.1093/jtm/taaa031/5775501

Harrell Jr FE rms: Regression modeling strategies [Internet]. 2019;https://cran.r-project.org/package=rms. Accessed 13 May 2020

Subirana I, Sanz H, Vila J (2014) Building bivariate tables: the {compareGroups} package for {R}. J Stat Softw [Internet] 57:1–16 http://www.jstatsoft.org/v57/i12/. Accessed 13 May 2020

Gordon M Gmisc: Descriptive statistics, transition plots, and more [Internet]. 2020;https://cran.r-project.org/package=Gmisc. Accessed 13 May 2020

Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 382:2574–2577. https://doi.org/10.1056/NEJMc2009191CrossRefPubMed

Fernandes FM, Silva EP, Martins RR, Oliveira AG (2018) QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS One [Internet] 13:e0199028. https://doi.org/10.1371/journal.pone.0199028CrossRefPubMed

10.

Chorin E, Dai M, Shulman E, Wadhwani L, Cohen RB, Barbhaiya C et al (2020) The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. https://doi.org/10.1101/2020.04.02.20047050

11.

Yao T-T, Qian J-D, Zhu W-Y, Wang Y, Wang G-Q (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option. J Med Virol:1–8. https://doi.org/10.1002/jmv.25729

12.

Dayer MR, Taleb-Gassabi S, Dayer MS (2017) Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. Arch Clin Infect Dis 12. https://doi.org/10.5812/archcid.13823

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med [Internet]. https://doi.org/10.1056/NEJMoa2001282

14.

Nicholls JM, Poon LLM, Lee KC, Ng WF, Lai ST, Leung CY et al (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:1773–1778. https://doi.org/10.1016/S0140-6736(03)13413-7CrossRefPubMedPubMedCentral

15.

Song MM, Shuai K (1998) The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273:35056–35062. https://doi.org/10.1074/jbc.273.52.35056CrossRefPubMed

16.

Karlsen AE, Rønn SG, Lindberg K, Johannesen J, Galsgaard ED, Pociot F et al (2001) Suppressor of cytokine signaling 3 (SOCS-3) protects β-cells against interleukin-1β- and interferon-γ-mediated toxicity. Proc Natl Acad Sci U S A 98:12191–12196. https://doi.org/10.1073/pnas.211445998CrossRefPubMedPubMedCentral

17.

Fredeking T, Zavala-Castro J, Gonzalez-Martinez P, Moguel-Rodríguez W, Sanchez E, Foster M et al (2015) Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antiinfect Drug Discov 10:51–58. https://doi.org/10.2174/1574891x10666150410153839CrossRefPubMed

18.

Dai W, Zhang H, Yu J, Xu H, Chen H, Luo S et al (2020) CT imaging and differential diagnosis of COVID-19. Can Assoc Radiol J 71:084653712091303. https://doi.org/10.1177/0846537120913033CrossRef

19.

Tang L, He Y, Bai F, Luo B. The role of fever clinic during the COVID-19 pandemic: a case study of 1034 febrile patients. 2020 [cited 2020 12];https://www.researchsquare.com/article/rs-28368/latest.pdf. Accessed 13 Aug 2020

Titel: RETRACTED ARTICLE: A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort
verfasst von: Yasemin Cag
Sacit Icten
Burcu Isik-Goren
Naciye Betul Baysal
Begum Bektas
Ece Selvi
Pinar Ergen
Ozlem Aydin
Ayse Canan Ucisik
Fatma Yilmaz-Karadag
Hulya Caskurlu
Tulin Akarsu-Ayazoglu
Hasan Kocoglu
Sinan Uzman
Muge Nural-Pamukcu
Ferhat Arslan
Gurhan Bas
Mahmut Tayyar Kalcioglu
Haluk Vahaboglu
Publikationsdatum: 27.08.2020
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 2/2021
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-020-04016-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

RETRACTED ARTICLE: A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

COVID-19 IgG/IgM antibody testing in Los Angeles County, California

Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease

Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection

Extensively drug-resistant Acinetobacter baumannii carrying blaOXA-23-like and armA in a hospital after an intervention in the intensive care unit which ended a long-standing endemicity

Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach

How are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC)

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin